The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 371-376

  Tsuta, Koji ^a   Kawago, Mitsumasa ^a   Inoue, Eisuke ^b   Yoshida, Akihiko ^a   Takahashi, Fumiaki ^b   Sakurai, Hiroyuki ^a   Watanabe, Shun ichi ^a   Takeuchi, Masahiro ^b   Furuta, Koh ^a   Asamura, Hisao ^a   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma of the lung; ALK; EGFR; IASLC classification; KRAS

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC CORRELATION; HUMAN; LUNG ADENOCARCINOMA; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SMOKING; TUMOR VOLUME;

ADENOCARCINOMA OF THE LUNG; ALK; EGFR; IASLC CLASSIFICATION; KRAS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENES, RAS; GENETIC VARIATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; SOCIETIES, MEDICAL; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84881662088     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.012     Document Type: Article

References (40)

1. Travis W.D., Bramblla E., Muller-Hermelink H.K., Harris C.C. Pathology and genetics of tumors of the lung, pleura, thymus and heart 2004, IARC Press, Lyon (France).
2. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
3. Motoi N., Szoke J., Riely G.J., Seshan V.E., Kris M.G., Rusch V.W., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32:810-827.
4. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
5. Kim Y.H., Ishii G., Goto K., Nagai K., Tsuta K., Shiono S., et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004, 10:7311-7317.
6. Yoshizawa A., Motoi N., Riely G.J., Sima C.S., Gerald W.L., Kris M.G., et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011, 24:653-664.
7. Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A. Does lung adenocarcinoma subtype predict patient survival?.: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011, 6:1496-1504.
8. Warth A., Muley T., Meister M., Stenzinger A., Thomas M., Schirmacher P., et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012, 30:1438-1446.
9. Gu J., Lu C., Guo J., Chen L., Chu Y., Ji Y., et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-a single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol 2012, 107:474-480.
10. Goldstraw P. International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology. 2009.
11. Takano T., Ohe Y., Tsuta K., Fukui T., Sakamoto H., Yoshida T., et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res 2007, 13:5385-5390.
12. Yoshida A., Tsuta K., Nitta H., Hatanaka Y., Asamura H., Sekine I., et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011, 6:1677-1686.
13. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
14. R Development Core Team A language and environment for statistical computing 2011, R Foundation for Statistical Computing, Vienna, Austria. http://www.r-project.org/.
15. Pepe M.S., Janes H., Longton G., Leisenring W., Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159:882-890.
16. Cook N.R., Paynter N.P. Performance of reclassification statistics in comparing risk prediction models. Biom J 2011, 53:237-258.
17. Noguchi M., Morikawa A., Kawasaki M., Matsuno Y., Yamada T., Hirohashi S., et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995, 75:2844-2852.
18. Suzuki K., Yokose T., Yoshida J., Nishimura M., Takahashi K., Nagai K., et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000, 69:893-897.
19. Daly R.C., Trastek V.F., Pairolero P.C., Murtaugh P.A., Huang M.S., Allen M.S., et al. Bronchoalveolar carcinoma: factors affecting survival. Ann Thorac Surg 1991, 51:368-376. [discussion 76-7].
20. Garfield D.H., Cadranel J., West H.L. Bronchioloalveolar carcinoma: the case for two diseases. Clin Lung Cancer 2008, 9:24-29.
21. Kurokawa T., Matsuno Y., Noguchi M., Mizuno S., Shimosato Y. Surgically curable "early" adenocarcinoma in the periphery of the lung. Am J Surg Pathol 1994, 18:431-438.
22. Borczuk A.C., Qian F., Kazeros A., Eleazar J., Assaad A., Sonett J.R., et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009, 33:462-469.
23. Kim E.A., Johkoh T., Lee K.S., Han J., Fujimoto K., Sadohara J., et al. Quantification of ground-glass opacity on high-resolution CT of small peripheral adenocarcinoma of the lung: pathologic and prognostic implications. AJR Am J Roentgenol 2001, 177:1417-1422.
24. Lin D.M., Ma Y., Zheng S., Liu X.Y., Zou S.M., Wei W.Q. Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma. Histol Histopathol 2006, 21:627-632.
25. Xu L., Tavora F., Battafarano R., Burke A. Adenocarcinomas with prominent lepidic spread: retrospective review applying new classification of the American Thoracic Society. Am J Surg Pathol 2012, 36:273-282.
26. Funai K., Sugimura H., Morita T., Shundo Y., Shimizu K., Shiiya N. Lymphatic vessel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma. Ann Surg Oncol 2011, 18:2968-2972.
27. Yokose T., Suzuki K., Nagai K., Nishiwaki Y., Sasaki S., Ochiai A. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3cm or less in diameter. Lung Cancer 2000, 29:179-188.
28. Shimada Y., Saji H., Yoshida K., Kakihana M., Honda H., Nomura M., et al. Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage is non-small-cell lung cancer after complete surgical resection. J Thorac Oncol 2012, 7:1263-1270.
29. Brechot J.M., Chevret S., Charpentier M.C., Appere de Vecchi C., Capron F., Prudent J., et al. Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma. Correlation with TNM stage and disease free and overall survival. Cancer 1996, 78:2111-2118.
30. Fujita A., Kameda Y., Goya T. Clinicopathology of stromal invasion in lung adenocarcinoma. Pathol Int 2009, 59:1-6.
31. Bosl G.J., Bajorin D., Sheinfeld J., Motzer R. Cancer of the testis. Cancer: principles and practice of oncology 1977, 1397-1425. J.B. Lippincott, Philadelphia. 5th ed. V.T. Devita, S. Hellman, S. Rosenberg (Eds.).
32. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-6837.
33. Shim H.S., Lee da H., Park E.J., Kim S.H. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 2011, 135:1329-1334.
34. Zhang Y., Sun Y., Pan Y., Li C., Shen L., Li Y., et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012, 18:1947-1953.
35. Marchetti A., Buttitta F., Pellegrini S., Chella A., Bertacca G., Filardo A., et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996, 179:254-259.
36. Finberg K.E., Sequist L.V., Joshi V.A., Muzikansky A., Miller J.M., Han M., et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007, 9:320-326.
37. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15:3143-3149.
38. Nishino M., Klepeis V.E., Yeap B.Y., Bergethon K., Morales-Oyarvide V., Dias-Santagata D., et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 2012.
39. Thunnissen E., Beasley M.B., Borczuk A.C., Brambilla E., Chirieac L.R., Dacic S., et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012, 25:1574-1583.
40. Warth A., Cortis J., Fink L., Fisseler-Eckhoff A., Geddert H., Hager T., et al. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch 2012, 461:185-193.